Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Provides Controlled IL-12 Update with Positive Data from Phase 1 Trial Presented at Annual Meeting of the Society for Neuro-Oncology
Ad-RTS-hIL-12 plus 20mg veledimex (Controlled IL-12) determined to be preferred dosing with low-dose steroids to treat adult patients with recurrent glioblastoma Median overall survival for Ad-RTS-hIL-12 plus veledimex in patients receiving low-dose steroids is 17.8 months Controlled IL-12
View HTML
Toggle Summary Ziopharm Oncology to Host Conference Call Today at 8 a.m.
BOSTON , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today will host a webcast and conference call today, Nov. 12 , at 8 a.m. ET . On the call, management will discuss recent corporate developments and the new collaboration with Regeneron Pharmaceuticals .
View HTML
Toggle Summary Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer
BOSTON , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. , (Nasdaq:ZIOP) today announced a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in combination with Regeneron’s PD-1 antibody Libtayo ® (cemiplimab-rwlc) to treat
View HTML
Toggle Summary Ziopharm Oncology Announces $50 Million Private Placement
BOSTON , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that it has entered into definitive securities purchase agreements for the sale of its common stock and warrants to purchase common stock in a private placement that is expected to result in gross
View HTML
Toggle Summary Ziopharm Oncology Third Quarter 2018 Financial Results Conference Call Rescheduled to Nov. 12
BOSTON , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that it has rescheduled its quarterly conference call to Monday, Nov. 12 , at 8 a.m. ET to provide a corporate update and discuss financial results for the third quarter ended Sept.
View HTML
Toggle Summary Ziopharm Oncology to Present at the Stifel 2018 Healthcare Conference on Nov. 14
BOSTON , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer, will present at the Stifel 2018 Healthcare Conference in New York on Wednesday, Nov. 14 , at 1:15 p.m. ET .
View HTML
Toggle Summary Ziopharm Oncology to Present Update on Controlled IL-12 Brain Cancer Trial at Annual Meeting of the Society for Neuro-Oncology on Nov. 16
BOSTON , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced it will update data from its Phase 1 trial of
View HTML
Toggle Summary Ziopharm Oncology to Announce Third Quarter 2018 Financial Results, Host Conference Call Nov. 8
BOSTON , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, Nov. 8 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the third quarter ended
View HTML
Toggle Summary Ziopharm Oncology Announces Changes to Board of Directors and Management Team
-- CEO Laurence Cooper Appointed to Board of Directors  -- Francois Lebel to Depart Company BOSTON , Oct. 16, 2018 (GLOBE NEWSWIRE) --   Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies
View HTML
Toggle Summary Ziopharm and Precigen Redefine Relationships, Announce New License Agreement
Ziopharm to Host Conference Call at 8 a.m. BOSTON and GERMANTOWN, Md., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) and Precigen, Inc. , a wholly-owned subsidiary of Intrexon Corporation (Nasdaq: XON), today announced a new definitive license agreement to replace all
View HTML